



# Intravenous drug user infections



#### Dale Fisher

Professor, Yong Loo Lin School of Medicine, National University of Singapore

Head Of Infectious Diseases Division & Senior Consultant, National University Hospital, Singapore







**Procedures** 

Outpatient Infusion Clinic (OPIC)

Outpatient Parental Antibotics Therapy (OPAT)

# Should we be treating IVDU patients in OPAT?

- Any policies for treating IVDU patients with OPAT (appropriately) offer little guidance
- ☐ It can be argued that (more than anyone) a proactive stance is needed
- Improving treatment models in IVDU patients could lead to improved patient compliance and therefore outcomes in addition to cost savings
- ☐ Inclusion of IVDU patients at NUH OPAT since 2005

## Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement.

#### Patient selection.

- 2.1 It is the responsibility of the infection specialist to agree specific infection-related inclusion and exclusion criteria for OPAT. These should incorporate specific infection severity criteria where appropriate.
- 2.2 There should be agreed and documented OPAT <u>patient suitability</u> criteria incorporating physical, social and logistic criteria. These should be documented for each patient.
- 2.3 Initial assessment for OPAT should be performed by a <u>competent member</u> of the OPAT team.
- 2.4 <u>Patients and carers</u> should be fully informed about the nature of OPAT and should be given the opportunity to decline or accept this mode of therapy.
- 2.5 All patients who have been assessed as being at risk of venous thrombosis as inpatients should be considered for further prophylaxis during OPAT if assessed as having ongoing risk.

# OPAT Patient Enrolment Checklist

- Diagnosis and treatment plan is confirmed by an Infectious Disease physician
- Medically stable
- Patient understands the diagnosis and treatment (including compulsory attendance and PICC/infusor care)
- Patient understands OPAT and emergency numbers
- Adequate care of home needs (by self or family)
- Patient future contact arranged (ie. will come to infusion center each day or as scheduled, nurses to visit home commencing on date scheduled)
- Consideration of caregiver home administration made
- Financial counseling completed
- Adequate IV access (ie PICC, daily insertion, IV in site);
- Other nursing care needs identified (ie; wound care)



#### What Can we do for our Patients?

Expected: PICC care, antibiotic decisions and

monitoring, clinical, serological & radiologic

response monitoring, address ADRs

In addition: Dressings, BSLs, INR, wounds, drain care

And Now: PICC insertions

But are we always as patient centred as we could be?



#### Patient selection; crucial

- Eligibility criteria:
  - Adequate housing
  - Reliable guardian
- Signed contract:
  - Compliance with <u>daily</u> OPAT clinic reviews
  - Will not access PICC line
  - Will not take any drugs not prescribed by hospital
  - Zero tolerance



#### Outpatient Parenteral Antibiotic Therapy (OPAT)

Signature

Letter of Agreement	
I,(NRIC:	T: hereby agree to comply
<ol> <li>Do not misuse my Peripherally Inserted Centra</li> <li>Do not tamper with the security seals on infuse</li> <li>Do not take any other drugs that are not prescr</li> <li>Others (please specify)</li> </ol>	or and on PICC.
I have been counselled for the following:	
<ol> <li>The consequences of misusing of the PICC.</li> <li>The consequences of misusing of drugs.</li> </ol>	
I understood that I would be handed to the police if an	y of the above is not complied.
Name and Signature of patient	Date
Name of Doctor/Nurse and	 Date


#### Preventing PICC abuse – Security Seals







#### Preventing PICC abuse - Security Seals



#### Prevention strategies

- Patient & family/guardian education
  - Appropriate care of PICC
  - Hazards of PICC abuse
  - Zero tolerance policy
- Formal drug counseling
  - At start of treatment and subsequently on an as needed basis
- Urine drug screens
- Open, non-judgmental communication

# STUDY OF IVDU PATIENTS AT NUH OPAT

#### Study of IVDU patients in OPAT

- □ Prospective observational study of IVDU patients in NUH OPAT center: Jan 05 − Dec 09
- Aim: to assess the safety and efficacy of treating IVDU patients in OPAT
- Selected hospitalized patients were enrolled with various strategies utilized to optimize safety & efficacy


### **Study Outcomes**

- Mortality
- Completion of therapy
- □ PICC abuse
- Readmissions for complications during OPAT and a 30 day follow-up
  - Infection related
  - Treatment related

### Subject Characteristics


- 29 IVDU patients
  - 3.2% total OPAT patients
- □ Median age 41 (26 53)
- □ 90% male





### **Subject Characteristics**


#### **Ethnicity in study**



#### Ethnicity in Singapore

- Chinese 76.4%
- Malay 14.9%
- Indian 6.4%


## Type of Intravenous Drug Use







## Type of Infection




**New Diagnosis** 

HIV - 2

Hepatitis C - 3

### Micro-organisms & Antibiotic



### Hospital Admission

- □ Median length of hospital stay: <u>15 days</u> (2-48)
- □ 6 patients (20.7%) required ICU management
- □ 2 patients (6.9%) absconded
  - → readmitted with sepsis → subsequently successfully treated in OPAT

#### **OPAT Treatment**

- Median length of OPAT Treatment: <u>17 days</u> (1-85)
   (675 patient treatment days)
- 97% patients completed treatment in OPAT (6 readmitted to hospital but 5 returned to OPAT
- Complications during OPAT:

Complication	Number (%)	Comment
PICC infection	2 (7)	Similar rate of PICC infections seen in general OPAT population
PICC abuse	О	Indicated by absence of security seal tampering
Deaths	O	No deaths during OPAT treatment or follow-up period

# Unscheduled readmission rates during OPAT & follow-up

Patient	Initial Infection	No. OPAT Rx days prior to re- admission	Reason for readmission	Return to OPAT for completion of Rx
<b>During O</b>	PAT Rx : 5 patie	ents (17.2%)		
1	Osteomyelitis, MSSA	12	PICC infection, Pseudomonas aeruginosa	Yes
2	Endocarditis, MSSA	5	Worsening <u>lung emboli</u> plus <u>bacteraemia</u> , Streptococcus salivarius	Yes
3	Endocarditis, MSSA	3	PICC infection, Klebsiella pneumoniae	Yes
4	Endocarditis, MSSA	15	Haemophilus influenzae <u>bacteraemia</u>	Yes
5	Endocarditis, MSSA	14	Worsening vegetations & valvular dysfunction	No
During follow-up period after OPAT : 1 patient				
1	Endocarditis, MSSA	14*	Streptococcal sp bacteremia	Yes

<sup>\*</sup> Number of days post completion of OPAT

## Comparison of re-admission rates in general OPAT population

Study	No. of patients in study	Type of Infection	Unscheduled readmission rates	
This Study	29	Infective endocarditis 42% Bone/joint 27% Soft tissue 7%	20.7%	
Studies in non-IVDU patients				
Larioza J, Heung L et al¹	43	Infective endocarditis 100%	23%	
Fisher DA, Kurup A, Lye D et al <sup>2</sup>	225	Bone/joint 39.2% Soft tissue 9.1% Infective endocarditis 7.5%	8.9%	
Nathwani D, Morrison J et al <sup>3</sup>	101	Soft tissue 51.5% Bone/joint 22.8% Infective endocarditis 3.9%	7.5%	

<sup>1</sup> Southern Med J 102(6) June 09 575-579. Management of infective endocarditis in outpatients: clinical experience with OPAT

<sup>2</sup> Int J Antimicr Agents 28 (2006) 545-550. Outpatient parenteral antibiotic therapy in Singapore

<sup>3</sup> Health Bull 57 (1999) 332-7. Outpatient and home parenteral antibiotic therapy: evaulation of the impact of one year's experience in Tayside

### Summary

- Infective endocarditis was the most common infection
- MSSA was the most common organism
- Out of the 29 patients
  - 23 completed treatment uneventfully
  - 5 required hospital re-admission
  - 1 defaulted from OPAT treatment
- ☐ There were no cases of PICC abuse
- Unscheduled readmissions (including PICC infections) were NOT more common

#### Conclusion

- "Package Intervention" careful selection, counseling, prevention strategies and monitoring of IVDU patients in OPAT
  - → safe and successful treatment

 Some patients are likely to do better with outpatient treatment, compared to inpatient management

# International approaches to treating IVDU patients in OPAT

The use of OPAT in IVDU patients is controversial & it is unknown what the approaches and outcomes of these patients are from around the world

□ An international survey was conducted to gain a better understand of this issue

#### Methods

- A survey was conducted using an on-line survey program from May to October 2010 to OPAT centres from around the world.
- □ Issues addressed:
  - the approach of health institutions on the treatment of IVDU patients requiring prolonged parenteral antibiotics
  - the outcomes of IVDU patients treated with OPAT
  - the providers' concerns and views on this form of therapy

#### Results


- □ 64 OPAT centres participated:
  - Australia 29, New Zealand 8
  - Asia (India and Singapore) 4
  - North America 13
  - United Kingdom 8
  - Europe (Italy) 2


#### Results


- The majority of centers (84.4%)
   treat patients with a history of IVDU
- □ 44.2% use PICCs
- Most (84%) believe that the use of OPAT in IVDU patients is beneficial and outweighs the risks with little inter-regional variation in this approach and opinion.

	Question and multi-choice responses	Number of responses (%)	
1.	Approximately what percentage of your OPAT patients are current or recent IVDUs?		
	<1	23 (42.6)	
	1-5	26 (48.1)	
	5-10	5 (9.3)	
	>10	0	
Do yo	ou allow PICCs to be used in current or recent IVDU patients?		
	Yes, most of the time	23 (44.2)	
	Yes, but use alternatives as much as possible (eg intramuscular injections, removal of	21 (40.4)	
	needle after infusion)	8(15.4)	
	Never	` ′	
1.	What routine measures are used in your centre when treating current or recent IVDU		
	patients? (colect all that apply)		
	Counselling on compliance and risk of PICC abuse	38 (74.5)	
	Substance abuse counselling	28 (54.9)	
	No home infusions	17 (33.3)	
	Signed contract	16 (31.4)	
	Urine drug screens	8 (15.7)	
	Tamper proof seals/dressings over PICCs	3 (5.9)	Remarkably liberal
1.	What is your policy with respect to patients suspected of IVDU during OPAT?		Tromanably liberal
	IVDU is not tolerated	34 (65.4)	
	IVDU is tolerated as long as PICC is not abused	15 (28.8)	
	PICC abuse tolerated as long as patient compliant with attendance	3 (5.8)	
1.	Approximately what percentage of IVDU patients fail to follow-up with the OPAT plan		Generally successfu
	<5	31 (64.6)	_ Generally succession
	5-10	9 (18.8)	
	10-20	2 (4.2)	
	>20	6 (12.5)	
1.	What legal concerns do you have with treating IVDU patients in OPAT? (select all that apply)		
	Nil specific legal concerns	21 (42.0)	
	Inadequate safety and efficacy data	19 (38.0)	
	Inadequate follow up and support systems	18 (36.0)	
	Difficulties proving that patient is sufficiently informed and consented	12 (24.0)	
	Facilitation of drug abuse	6 (12.0)	concerns
1.	What other concerns do you have with treating IVDU patients in your OPAT? (select all that		
	apply)	23 (46.9)	
	Concerns for staff safety	21 (42.9)	
	Inadequate formal drug counselling and support	21 (42.9)	
	Extra demands on nursing time		
1.	Which statement best reflects your view on the treatment of IVDU patients in OPAT?		
	It is mostly safe and successful	14 (28.0)	
	It is less safe and successful than non-IVDUs but benefits outweigh risks	28 (56.0)	
	It is not safe and the whole system concerns me	8 (16.0)	


## International comparison of survey responses







Policy with respect to patients



#### Conclusion

- Around the world, OPAT centres are treating IVDU patients with acceptable outcomes
- This form of therapy is increasingly regarded as a beneficial and a preferred treatment option in selected patients

# International Society of Chemotherapy ......OPAT workgroup

- 1. share information on service models
- 2. create an international research agenda
- 3. support countries and institutions wishing to establish OPAT
- 4. formalise the relationship with industry.....pharma and devices with a view to facilitating the above

Doctors (adults and paeds), pharmacists and nurses from Singapore, Australia, New Zealand, Brunei, Japan, US, UK, Hong Kong

Dale Fisher; mdcfda@nus.edu.sg